On Nov 28, major Wall Street analysts update their ratings for $Sarepta Therapeutics (SRPT.US)$, with price targets ranging from $182 to $215.
Morgan Stanley analyst Matthew Harrison maintains with a buy rating, and maintains the target price at $200.
TD Cowen analyst Ritu Baral maintains with a buy rating, and maintains the target price at $203.
Oppenheimer analyst Andreas Argyrides maintains with a buy rating, and maintains the target price at $215.
Piper Sandler analyst Biren Amin maintains with a buy rating, and adjusts the target price from $200 to $182.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Following the announcement of Sarepta's agreement with Arrowhead to license several clinical and preclinical programs, an analyst commented positively on the potential enhancement to the company's portfolio. It was noted that this agreement not only strengthens the company's pipeline but also provides potential for additional revenue streams beyond its existing DMD franchise. This strategic move is viewed as a crucial step in diversifying Sarepta's offerings, alleviating investor concerns about reliance on single-event gene therapies.
The collaboration with Arrowhead provides a diversified platform with a definitive long-term investment in chronic strategies for rare diseases, and further diversifies the therapeutic areas through clinical programs addressing muscle, central nervous system, and pulmonary indications. The strategic rationale for this deal complements Sarepta's expertise in rare genetic medicine, and the initiation of a share buyback indicates confidence in near-term revenue prospects.
Here are the latest investment ratings and price targets for $Sarepta Therapeutics (SRPT.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月28日，多家華爾街大行更新了$Sarepta Therapeutics (SRPT.US)$的評級，目標價介於182美元至215美元。
摩根士丹利分析師Matthew Harrison維持買入評級，維持目標價200美元。
TD Cowen分析師Ritu Baral維持買入評級，維持目標價203美元。
奧本海默控股分析師Andreas Argyrides維持買入評級，維持目標價215美元。
派傑投資分析師Biren Amin維持買入評級，並將目標價從200美元下調至182美元。
此外，綜合報道，$Sarepta Therapeutics (SRPT.US)$近期主要分析師觀點如下：
在Sarepta與Arrowhead達成許可多個臨床和前臨床項目的協議後，一位分析師積極評價了這一協議對公司投資組合的潛在增強。指出此協議不僅增強了公司的產品管線，還提供了超越現有DMD業務的額外營業收入來源的潛力。這一戰略舉措被視爲多樣化Sarepta產品的重要一步，緩解了投資者對依賴單一事件基因療法的擔憂。
與Arrowhead的合作提供了一個多樣化的平台，對罕見疾病的慢性策略進行了明確的開多投資，並通過解決肌肉、中樞神經系統和肺部適應症的臨床項目進一步多樣化了治療領域。此交易的戰略理由與Sarepta在罕見遺傳醫學方面的專業知識相輔相成，而股票回購的啓動則表明對短期營業收入前景的信懇智能。
以下爲今日4位分析師對$Sarepta Therapeutics (SRPT.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
